Related Experiment Video
Updated: Jul 20, 2025

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022
Expression Profile, Molecular Association, and Clinical Significance of POLD4 in Glioblastoma
Md Tanjim Alam1, Mohammad Shadab Ali2,3, Harsh Goel2
1Cancer Biology & Inflammatory Disorder Division, CSIR-IICB Translational Research Unit of Excellence, CN-6, Salt Lake, Sector - V, Kolkata, WB, 700091, India.
Abstract:
The POLD4 gene encodes a subunit (δ4) of DNA polymerase delta, which is a key enzyme involved in DNA replication and repair. Recent studies have suggested that POLD4 plays a crucial role in developing certain cancers. However, there is a lack of knowledge regarding the role of POLD4 in the context of glioblastoma (GBM). Therefore, in this study we have used various cancer bioinformatics tools to explore the role of POLD4 in glioblastoma. Data from various sources were accessed to analyze POLD4 gene expression and estimate tumor-infiltrating immune cells in glioblastoma. Methylation data were retrieved using the MEXPRESS web browser and analyzed. UALCAN webserver was used to analyze the protein expression of POLD4. Gene correlation and pathway enrichment analysis were performed using cBioPortal and GSEA software, respectively. Afterward, survival analysis was performed. POLD4 was significantly upregulated in glioblastoma at both gene and protein levels in GBM, and ROC curve analysis revealed it as a potential biomarker in glioblastoma. GSEA analysis of TCGA-GBM pan-cancer study exhibited that POLD4 expression was associated with critical pathways, such as interferon-gamma response, G2M checkpoint, inflammatory response, E2F targets, EMT transition, and KRAS signaling pathways. Furthermore, POLD4 expression was positively correlated with DNA methylation at 3 CpG sites, including Cg16509978, with a Pearson correlation coefficient value of 0.398 (p-value ≤ 0.01), while the promoter region had a positive correlation but was not significant. In addition, POLD4 is significantly linked with poor OS, PFS, and DFS. We also found association of POLD4 expression with altered immune cell infiltration. In conclusion, POLD4 is significantly upregulated in glioblastoma and may be used as a potential diagnostic or prognostic biomarker for GBM patients. However, to establish the same a large cohort study is needed. Using TCGA data and various cancer bioinformatics tools mentioned above we observed very high level of gene and protein expression of POLD4 in glioblastoma patients. The expression of POLD4 was significantly correlated with inflammatory and oncogenic pathways and it also has a significant correlation with adverse outcome in patients with glioblastoma.
Insights
The POLD4 gene is highly expressed in glioblastoma (GBM), correlating with poor patient outcomes and immune cell infiltration. This suggests POLD4 may serve as a potential biomarker for GBM diagnosis and prognosis.
Area of Science:
- Molecular Biology
- Cancer Genomics
- Bioinformatics
Background:
- The POLD4 gene encodes a subunit of DNA polymerase delta, crucial for DNA replication and repair.
- Emerging evidence links POLD4 to various cancers, but its role in glioblastoma (GBM) remains under-explored.
Purpose of the Study:
- To investigate the role and potential of POLD4 as a biomarker in glioblastoma using bioinformatics tools.
- To analyze POLD4 gene and protein expression, methylation status, and its correlation with clinical outcomes and immune infiltration in GBM.
Main Methods:
- Utilized cancer bioinformatics tools (MEXPRESS, UALCAN, cBioPortal, GSEA) to analyze TCGA-GBM data.
- Assessed POLD4 gene/protein expression, DNA methylation, immune cell infiltration, and survival outcomes (OS, PFS, DFS).
- Performed gene correlation and pathway enrichment analysis (GSEA).
Main Results:
- POLD4 was significantly upregulated at both gene and protein levels in glioblastoma.
- POLD4 expression correlated positively with DNA methylation at specific CpG sites and was associated with critical oncogenic pathways (e.g., interferon-gamma response, EMT).
- Elevated POLD4 expression was linked to poor overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS), and altered immune cell infiltration.
Conclusions:
- POLD4 is a significantly upregulated gene in glioblastoma and shows potential as a diagnostic or prognostic biomarker.
- POLD4 expression is associated with key cancer-related pathways and adverse clinical outcomes in GBM patients.
- Further large-scale studies are warranted to validate POLD4's utility as a GBM biomarker.

